Merisaari H, Laakso H, Liljenback H, Virtanen H, Aronen H, Minn H
Front Oncol. 2021; 11:583921.
PMID: 34123770
PMC: 8188898.
DOI: 10.3389/fonc.2021.583921.
Yiew X, Bateman S, Hahn R, Bersenas A, Muir W
Front Vet Sci. 2020; 7:587106.
PMID: 33330713
PMC: 7714761.
DOI: 10.3389/fvets.2020.587106.
Liu H, Daar E, Wang Y, Siqueiros L, Campbell K, Shen J
AIDS Res Hum Retroviruses. 2019; 36(1):65-74.
PMID: 31516025
PMC: 6944136.
DOI: 10.1089/AID.2019.0202.
Hambuchen M, Hendrickson H, Gunnell M, McClenahan S, Ewing L, Gibson D
Drug Alcohol Depend. 2017; 179:347-354.
PMID: 28844011
PMC: 5600196.
DOI: 10.1016/j.drugalcdep.2017.07.011.
Quach H, Yang Q, Chow E, Mager D, Hoi S, Pang K
Br J Pharmacol. 2015; 172(14):3611-26.
PMID: 25829051
PMC: 4507163.
DOI: 10.1111/bph.13153.
Evaluation of a computer program for non-invasive determination of pulmonary shunt and ventilation-perfusion mismatch.
Lockwood G, Fung N, Gareth Jones J
J Clin Monit Comput. 2014; 28(6):581-90.
PMID: 24402641
DOI: 10.1007/s10877-014-9554-x.
Pharmacokinetic determinants in the design and evaluation of sustained-release dosage forms.
Boxenbaum H
Pharm Res. 2013; 1(2):82-8.
PMID: 24277217
DOI: 10.1023/A:1016355431740.
Clinical pharmacokinetics of buffered propranolol sublingual tablet (Promptol™)-application of a new "physiologically based" model to assess absorption and disposition.
Wang Y, Wang Z, Zuo Z, Tomlinson B, Lee B, Bolger M
AAPS J. 2013; 15(3):787-96.
PMID: 23605805
PMC: 3691420.
DOI: 10.1208/s12248-013-9479-1.
Single- and multiple-dose kinetics of oral lorazepam in humans: the predictability of accumulation.
Greenblatt D, Allen M, MacLaughlin D, Huffman D, Harmatz J, Shader R
J Pharmacokinet Biopharm. 2010; 7(2):159-79.
PMID: 20218012
DOI: 10.1007/BF01059736.
A multi-component model of the dynamics of salt-induced hypertension in Dahl-S rats.
McLoone V, Ringwood J, Van Vliet B
BMC Physiol. 2009; 9:20.
PMID: 19874603
PMC: 2785758.
DOI: 10.1186/1472-6793-9-20.
Tumor-growth-promoting cyclooxygenase-2 prostaglandin E2 pathway provides medulloblastoma therapeutic targets.
Baryawno N, Sveinbjornsson B, Eksborg S, Orrego A, Segerstrom L, Oqvist C
Neuro Oncol. 2008; 10(5):661-74.
PMID: 18715952
PMC: 2666243.
DOI: 10.1215/15228517-2008-035.
Pharmacokinetics and safety of a fully human hepatocyte growth factor antibody, AMG 102, in cynomolgus monkeys.
Kakkar T, Ma M, Zhuang Y, Patton A, Hu Z, Mounho B
Pharm Res. 2007; 24(10):1910-8.
PMID: 17520181
DOI: 10.1007/s11095-007-9316-2.
Non-linear mixed effects modeling - from methodology and software development to driving implementation in drug development science.
Pillai G, Mentre F, Steimer J
J Pharmacokinet Pharmacodyn. 2005; 32(2):161-83.
PMID: 16283536
DOI: 10.1007/s10928-005-0062-y.
Phase I and pharmacokinetic study of fostriecin given as an intravenous bolus daily for five consecutive days.
Le L, Erlichman C, Pillon L, Thiessen J, Day A, Wainman N
Invest New Drugs. 2004; 22(2):159-67.
PMID: 14739664
DOI: 10.1023/B:DRUG.0000011792.13160.b0.
Pharmacokinetics of sodium borocaptate: a critical assessment of dosing paradigms for boron neutron capture therapy.
Gibson C, Staubus A, Barth R, Yang W, Ferketich A, Moeschberger M
J Neurooncol. 2003; 62(1-2):157-69.
PMID: 12749711
DOI: 10.1007/BF02699942.
Pharmacokinetics of oxaliplatin in humans.
Ehrsson H, Wallin I, Yachnin J
Med Oncol. 2003; 19(4):261-5.
PMID: 12512920
DOI: 10.1385/MO:19:4:261.
Risedronate pharmacokinetics and intra- and inter-subject variability upon single-dose intravenous and oral administration.
Mitchell D, Barr W, Eusebio R, STEVENS K, Duke F, Russell D
Pharm Res. 2001; 18(2):166-70.
PMID: 11405286
DOI: 10.1023/a:1011024200280.
Comparative pharmacokinetics, tissue distributions, and effects on renal function of novel polymeric formulations of amphotericin B and amphotericin B-deoxycholate in rats.
Echevarria I, Barturen C, Renedo M, Troconiz I, Dios-Vieitez M
Antimicrob Agents Chemother. 2000; 44(4):898-904.
PMID: 10722488
PMC: 89789.
DOI: 10.1128/AAC.44.4.898-904.2000.
Effect of renal function on risedronate pharmacokinetics after a single oral dose.
Mitchell D, St Peter J, Eusebio R, Pallone K, Kelly S, Russell D
Br J Clin Pharmacol. 2000; 49(3):215-22.
PMID: 10718776
PMC: 2014925.
DOI: 10.1046/j.1365-2125.2000.00135.x.
Bioavailability of aciclovir after oral administration of aciclovir and its prodrug valaciclovir to patients with leukopenia after chemotherapy.
Steingrimsdottir H, Gruber A, Palm C, Grimfors G, Kalin M, Eksborg S
Antimicrob Agents Chemother. 1999; 44(1):207-9.
PMID: 10602752
PMC: 89657.
DOI: 10.1128/AAC.44.1.207-209.2000.